Evidence map›Paper›PMID 38397466›Full record

ReviewBiomolecules2024

Updates and Challenges in ENS Cell Therapy for the Treatment of Neurointestinal Diseases.

Takahiro Ohkura, Alan J Burns, Ryo Hotta

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Takahiro OhkuraDepartment of Pediatric Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-4168-167X
Alan J BurnsDepartment of Pediatric Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Ryo HottaDepartment of Pediatric Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-9890-8241
Harvard University · US

Funding

Characterizing neurogenic progenitors in the adult intestineR01DK119210 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ALLAN M GOLDSTEIN · 2020 to 2026
$2.5M
Uncovering the therapeutic potential of adipose tissue derived neural stem cells for Hirschsprung's disease.R21HD106036 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI GOLDSTEIN, ALLAN M, STAVELY, RHIAN · 2022 to 2023
$452k
NICHD NIH HHS R21 HD106036NIDDK NIH HHS R01 DK119210
6 · The paper itself

Abstract

Neurointestinal diseases represent a significant challenge in clinical management with current palliative approaches failing to overcome disease and treatment-related morbidity. The recent progress with cell therapy to restore missing or defective components of the gut neuromusculature offers new hope for potential cures. This review discusses the progress that has been made in the sourcing of putative stem cells and the studies into their biology and therapeutic potential. We also explore some of the practical challenges that must be overcome before cell-based therapies can be applied in the clinical setting. Although a number of obstacles remain, the rapid advances made in the enteric neural stem cell field suggest that such therapies are on the near horizon.

Indexed as

Enteric Nervous SystemNeural Stem CellsCell- and Tissue-Based TherapyIntestine, Smallcell therapycell transplantationenteric neural crest-derived cellsneurointestinal diseasesregenerative medicine

Identifiers

PMID38397466
PMCPMC10887039
OpenAlexW4391879456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.